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The Comparison of Service Models of Warfarin Monitoring in Calderdale and Huddersfield 
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ABSTRACT
Background: Warfarin-related knowledge and patient satisfaction with warfarin monitoring 
services are generally high with respect to anticoagulation-related care received. Providing a 
cost-effective warfarin monitoring service while improving warfarin-related knowledge, patient 
safety and satisfaction can be challenging.
Objectives: To compare ‘post and dose' service offered by the Calderdale Royal Hospital (CRH) 
and ‘face-to-face’ service offered by Huddersfield Royal Infirmary (HRI) in terms of costs of 
service delivery, patient satisfaction, warfarin-related knowledge and safety indicators. 
Methods: A cross-sectional sample of 160 patients on long-term warfarin therapy from 
anticoagulation (outpatient) clinics at CRH and HRI using interviewer-administered data 
collection form. International Normalized Ratio (INR), Time in Therapeutic Range (TTR) and 
Variance Growth Rate (VGR) values of last 12 months and the data on costs of service delivery, 
knowledge and satisfaction were collected. 
Results: Patients monitored at HRI had higher mean VGR value (0.35 ± 0.62 vs. 0.17 ± 0.17, 
p=0.092) and slightly lower mean TTR (68.70 ± 19.43 vs. 69.63 ± 17.71, p=0.756) compared with 
CRH patients. Patients monitored in ‘post and dose’ were estimated at a price of £11.06 per 
patient per visit and each patient in face-to-face service only cost £9.70 per visit. Patients 
monitored at HRI had marginally higher overall knowledge score (65.22 ± 23.29 vs. 60.31 ± 20.93, 
p=0.165) and overall satisfaction score (15.59 ± 3.16 vs. 15.05 ± 3.10, p=0.279) compared with 
CRH patients. A positive and significant correlation was found between patients’ knowledge and 
patient satisfaction (r=+0.327, p=0.001).
Conclusion: Although, HRI provided monitoring service at a slightly lower cost than CRH, patients 
monitored at CRH had better anticoagulation control and favourable indicators. Warfarin-related 
knowledge needs to be improved to achieve further improvement in quality of warfarin use.
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The Comparison of Service Models of Warfarin Monitoring in Calderdale and Huddersfield 
Foundation Trust Hospitals in West Yorkshire, UK
1. Introduction
Warfarin is the most commonly prescribed oral anticoagulant in the UK.1 It is estimated that 
there are between 500,000 and 1 million people in the UK currently on oral anticoagulant 
therapy.2 Vitamin K antagonists such as warfarin are the first line of treatment in several 
thrombotic diseases.3,4 Patient safety can be enhanced by specialised anti-coagulation clinics 
that optimise warfarin effectiveness and minimise the safety risks. Several studies showed 
that patients who are regularly monitored at anticoagulation clinics are more aware of 
interactions.5-7 Hasan et al., (2011) concluded that patients in pharmacist-managed 
anticoagulation clinics had better INR control in comparison to patients from physician 
therapy adherence clinics.6 A meta-analysis also found that pharmacist-led clinics had 
improved clinical outcomes for patients; especially surrounding the reduced risk of bleeding 
complications.7 
Cost is an important factor when comparing warfarin monitoring services. An English study 
(2014) looking at the cost of monitoring elderly patients taking warfarin over 3 care settings; 
in hospital, in general practice and in a domiciliary setting concluded that patients who had 
domiciliary monitoring had a lower TTR (68%) compared to those in hospital and general 
practice, therefore costed the NHS more at a price of £222 per patient per annum (including 
cost of medication).8 Patients monitored in hospital were costed at a price of £128 per patient 
per annum and each patient in General Practice only cost £126 per annum per year. A 
systematic review (2010) of 29 studies found that staff time (19 studies; 66%) and 
measurement of INR (16 studies; 55%) were the most common costs associated with 
monitoring.9 With new models of monitoring continuously evolving to help cut costs, there 
are ideas surrounding patients being able to use self-testing techniques to monitor their INR. 
A Thailand based study comparing the cost-effectiveness of patient-self testing, 
anticoagulation clinic and usual care found that incremental cost-effectiveness ratios with 
self-testing was 128,697 (3625 USD) and 130,493 THB (3676 USD) per QALY gained compared 
with usual care and anticoagulation clinic, respectively. They concluded that patient-self 
testing is highly cost-effective compared with usual care and less cost-effective against 
anticoagulation clinic.10  
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Patient satisfaction is an essential factor of warfarin monitoring. It consists of a range of 
factors such as the arrangement of visits and satisfaction associated with staff. A study carried 
out by Carris et al., (2016) found that follow-up burden was reduced, and patient satisfaction 
improved with the addition of extended-interval monitoring.11 Similarly, improved patient 
satisfaction can also correlate with optimum anticoagulant control. A study by Kagansky et 
al., (2004) found that patients whose INR was in therapeutic range had a higher level of 
service satisfaction and were more satisfied with their anticoagulant education.12
Service monitoring is thought to cost the National Health Service (NHS) a great deal of money 
each year. Developments of new methods of monitoring are continually arising to help cut 
costs, and to allow patients to access services closer to home. It is apparent that there is a 
range of standard variables associated with warfarin monitoring services. This present study 
aims to compare two warfarin service models provided by two hospitals in the Calderdale and 
Huddersfield Foundation Trust (CHFT) in the West Yorkshire, United Kingdom. Our specific 
aims were to estimate the cost of both service models, patient satisfaction, warfarin-related 
knowledge and safety indicators.
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2. Methods
2.1. Study design and participants
This cross-sectional study was conducted amongst patients aged 18 and over who attended 
the Calderdale and Huddersfield Foundation Trust (CHFT) hospital (outpatient) clinics 
between January 2018 and February 2018 in the West Yorkshire, United Kingdom. All 
participants were required to give their written or verbal consent to partake. Participants 
would need to able to articulate, prescribed warfarin for longer than 6 months for any 
indication.
2.2. Monitoring services at HRI and CRH
Calderdale Royal Hospital (CRH) and Huddersfield Royal Infirmary (HRI) operate different 
services as they belong to different Clinical Commissioning Groups. CRH offers a ‘post and 
dose’ service. This consists of patient’s having their INR measured by a phlebotomist. The 
results are then sent to the patient via the anticoagulation department based at HRI in which 
the nurses adjust the dose of warfarin accordingly. Patients are contacted by telephone by 
the anticoagulation nurses with any dose adjustments and receive a dosing instruction letter 
in the post. The letter also contains INR reading and date of next appointment. Patients are 
instructed to paste the letter in their yellow warfarin book. The service is a walk-in service so 
that patients can attend at any time during their allocated appointment day.   
In contrast, HRI hosts a face to face clinic. This consists of the patient attending the hospital's 
anticoagulant clinic. An anticoagulation nurse carries out a finger-prick test and instantly 
provides the INR value. Dose adjustments are completed during the appointment and the 
dosing instructions are written in the patient’s anticoagulant book (yellow warfarin book) 
immediately. Patients must adhere to their allocated time slot. Both services use finger-pick 
method for INR measurement and is performed by a phlebotomist (at CRH) and a nurse (at 
HRI). The monitoring services at CRH and HRI are run by multidisciplinary team (e.g. 
pharmacist, nurse).
2.3. Data collection form 
An interviewer-administered data collection tool was used to gather patients’ demographic, 
prescribed medication, INR values over the last 12 months and information regarding the 
number of telephone calls, letters and clinic visits, indication and duration of warfarin 
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treatment. Four researchers (Ahmed N, Royle-Pryor A, Ahmed R and Brkic A) performed the 
interviews. Patients were also asked about hospital admissions in the previous year and 
whether the admission was related to warfarin. In addition to this, they were asked about 
whether they had experienced any side effects while on warfarin. Finally, whether they take 
their medication with supervision or support.  The data collection form is divided into 
following sections, evaluating certain aspects of the study aims.
2.4. Warfarin-related knowledge
Patients knowledge of warfarin treatment was assessed using 8-item questionnaire.6 The 
questionnaire included asking the patient if they were aware of interactions with warfarin 
and other medication, food or alcohol. They were also asked whether they thought the 
addition of a new medicine or a change of dose of current medicines would influence their 
INR.6 All 8 items were provided with options of ‘yes’, ‘no’ and ‘don’t know’. The questionnaire 
was found to be reliable (Cronbach alpha = 0.70). To identify the overall knowledge and 
satisfaction score, each answer was scored to achieve an overall percentage. A score of 1 was 
given for each correct answer. The percentage was calculated by dividing the number of 
correct answers by the total items.6 
2.5. Patient satisfaction
A 12-item questionnaire was used to identify patients’ satisfaction of the warfarin service. 
Patients were asked if they had a yellow warfarin book and if they were aware of when their 
next blood test was. They were also asked if they had received clear counselling on the use of 
warfarin, what to do in case of a missed dose and if they were aware of what to do in an 
emergency., Patient satisfaction was tested by asking patients to rate the care given by staff 
involved in the service, and a satisfaction rating for the service as a whole. These questions 
were developed by the anticoagulation monitoring service to assess satisfaction. The 
questionnaire was found to be reliable (Cronbach alpha = 0.74). The overall satisfaction score 
was achieved by scoring all participants in agreement as 1 or 2, and those that disagreed were 
given a value of 0, producing a possible range of 0 (not satisfied at all) to 21 (fully satisfied).
2.6. Costs of monitoring services
The estimated costs of the service monitoring per year was assessed by examining the two 
clinics that were operated at each base hospital. It did not take into account any satellite 
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clinics. The costs included professional fees (cost of anticoagulation team, e.g. nurses), the 
cost of consumables and the administrative costs. Although indirect costs to the patient is 
equally important, the present study was restricted to explore the direct costs of the 
monitoring service to the hospital trust including the two most common costs associated with 
monitoring: staff time and measurement of INR.9 
2.7. Anticoagulation control and safety indicators
The Time in Therapeutic Range (TTR) is an important indicator as it specifies the duration of 
time a patient's INR values lie within their target range. It is vital in assessing the control and 
intensity of warfarin therapy. However, it fails to measure the variance in INR readings. Thus, 
the Variance Growth Rate (VGR) is also required. The VGR value is an essential safety marker 
as it incorporates the variability and control while highlighting the risk of clinical events such 
as bleeding.13 
Using the patients DAWN (an electronic anticoagulation software) records, the patients INR 
measurements over the last 12 months, target range, TTR and VGR values were collected. TTR 
was categorised as excellent (TTR > 80%), good (TTR, 80–69%), average (TTR, 69–57%), below 
average (TTR, 57–39%) and poor (TTR < 39%).13 As per the DAWN records, the VGR when 
calculated over the previous 3 or 6 months, shows a strong correlation between bleeding 
events. To calculate the VGR, multiple methods can be used (e.g. the Fihn or the Cannegieter 
method).14 Regardless of VGR method, a higher VGR value indicate unstable anticoagulation 
and a lower VGR (close to 0) value indicates stable anticoagulation.13
An INR value of > 5 on two or more occasions in the past one year was considered as out of 
range (supratherapeutic INR). In addition to this, patients were asked for consent to access 
their Summary Care Records (SCRs) to provide a list of current prescribed medication, number 
of visits to the anticoagulation clinic, the number of INR tests performed, the number of 
postage from the anticoagulation clinic and the number of telephone calls from the 
anticoagulation clinic.
2.8. Sample size and sampling procedure
Using a software (Raosoft, Inc.), a required sample size of 149 was demonstrated (power 80%, 
distribution of response 50%, with 95% confidence interval). A total of 160 patients on 
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warfarin therapy aged 18 years and above participated in this study.15 Interviews were done 
immediately after their clinical encounter with the anticoagulation staff. Convenience 
sampling was used as the sampling method in this study. Patients were taken into a 
consultation room to carry out the interview. The study information sheets were shown or 
given (upon request), and consent (verbal and written) was obtained from each participant 
before participation in this study.
2.9. Ethics approval and confidentiality 
The ethics approval was obtained from the School of Applied Sciences Research and Ethics 
Committee (Project ID: SAS-REIC-18-1001-1). The study data had a separate code 
corresponding to the patients’ details. This was only accessible to the PI and stored in a 
password-protected file.
2.10. Statistical analysis
The data were analysed using SPSS (version 22) with 0.05 as the level of significance. 
Descriptive statistics were used to present percentages, frequencies, mean, median and 
standard deviation. Chi-Squared test was used to compare the characteristics of participants 
sociodemographic data. Where applicable, the p-value has been computed using the Chi-
squared test to distinguish whether the characteristics are statistically significant or not. 
Independent t-test was applied to compare the sites for mean INR, TTR and VGR values. 
Spearman correlation was used to assess the relationship between study variables (e.g. 
knowledge and satisfaction scores).
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3. Results
3.1. Socio-demographic variables of study participants
Table 1 shows that the average age of participants across two study sites was 70.61 ± 14.39. 
A large proportion of participants were between the age of 64-74 (26.3% of patients across 
both sites). Approximately, 74% of patients were above the age of 63. However, more 
participants between the ages of 18-63 were from HRI (28.7%) as opposed to CRH (22.5%). 
More than two-thirds (83.1%) of patients were on warfarin therapy for longer than 24 
months. Approximately 42% of patients from CRH and 41% from HRI. Only 3.8% of patients 
were on warfarin therapy for 6-12 months. Furthermore, the results show that half of the 
participants (50.6%)  had an indication atrial fibrillation. Whereas an indication of DVT was 
the least common; which consisted of 10% of sample group. 
3.2. Patients experience with warfarin treatment 
Table 2 displays that overall a quarter of the sample group was admitted to hospital in the 
last year; with 1.9% of patients being admitted to hospital on a warfarin-related incident. 
About 89% of the patients stated that they take their medication themselves. Approximately 
10% of patients from HRI and 16% from CRH, experienced side effects related to warfarin.  
3.3. Patients knowledge of warfarin
Overall, the average percentage of correct answers over both sites was 62.74% ± 22.19 (Table 
3). Comparing the overall average of correctly answered questions between both locations, 
HRI had an average of 65.22% ± 23.39, whereas CRH had an average of 60.31 ± 20.93%. A 
total of 102 patients answered correctly that warfarin affects the blood, whereas, 125 of the 
patients across both sites did not think warfarin thickens the blood. A positive and statistically 
significant correlation was found between patients’ knowledge and patients’ satisfaction 
(r=+0.327, p=0.001).
3.4. Patient satisfaction
Table 4 displays that half (56.6%) of the participants felt that they received explicit 
counselling. Almost 97.5% of patients across both sites, rated the care provided by staff at 
both locations as excellent. The warfarin service as a whole was ranked as excellent from a 
total of 158 (98.7%) patients. The overall satisfaction score for patients from HRI was 15.59 
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versus 15.05 from CRH. More than two-thirds of patients from HRI (91%) were told of the 
importance of blood monitoring, compared to 69% from HRI. 
3.5. Safety indicators 
Patients monitored at HRI had higher mean VGR value (0.35 ± 0.62 vs. 0.17 ± 0.17, p=0.092) 
and slightly lower mean TTR (68.70 ± 19.43 vs. 69.63 ± 17.71, p=0.756) compared with CRH 
patients. The average number of INR values above 5 (11.3%) for both places, with patients 
from HRI had slightly higher number than CRH (12.5 vs 10.0%, p=0.617). However, more 
patients from HRI (26.2%) achieved a TTR above 82% compared to 21.2% from CRH (Table 5). 
On average, ten patients across both sites had a poor TTR value (<39%). Despite this, patients 
in this category had an average knowledge score of 67.5% ± 19.7%. Also, patients with a poor 
TTR had an overall satisfaction score of 15.4% ± 3.8. Patients with INR readings above 5, 
generally scored a higher knowledge percentage (64.6% vs 62.5%) compared to patients with 
INR values below 5. 
3.6. Cost of service delivery
The service at HRI operates six clinics per week. Whereas, the clinic based at CRH delivers five 
clinics per week (Table 6). Although HRI provides more clinics, on average, they monitor 
nearly half the number of patients as opposed to CRH. From the data obtained, HRI monitored 
an average of 628 patients per month, while CRH monitored 1040 patients. The estimated 
costs (per patient per visit) at CRH, was approximately £11.06, whereas the cost of dosing a 
patient at HRI was an estimate of £9.70. 
Although the cost of these items was identical across both sites; CRH monitors more patients 
on average; thus, the cost of consumables will be considerably higher in comparison to HRI. 
However, this aspect of cost analysis is insignificant when comparing both service models 
within the CHFT.  Furthermore, the significant difference between services was the cost of 
professionals. CRH has more members of staff involved in the service, for example 
phlebotomist. 
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4. Discussion
The study examined the comparison between two warfarin monitoring services while 
assessing safety indicators, warfarin-related knowledge, patient satisfaction and the costs 
associated with running both services. Atrial fibrillation (AF) was the most common indication 
for warfarin therapy amongst patients in this study. The prevalence of AF increases with age 
and more men are likely to develop the condition.16,17 In 2016,  it was reported that 983,254  
people across England had atrial fibrillation.18 Similarly, research conducted in 2014 by NICE 
found that 34% of patients with atrial fibrillation were undergoing warfarin therapy. 
It is vital to consider patient safety when comparing a face-to-face clinic and a ‘post and dose’ 
service. Throughout the data collection process, several safety concerns were identified. 
Warfarin patients are required to carry a yellow anticoagulant therapy book and alert card. 
The book contains various details, including emergency contact details, information regarding 
the patients’ warfarin therapy, previous and current INR readings and warfarin doses.19 It was 
identified that 4 in 5 patients of our study carried a yellow warfarin book. More patients from 
HRI had a yellow warfarin booklet which may reflect on the type of service offered. 
The VGR value is found to be an essential safety marker as it gives the strongest association 
with clinical events such as bleeding.13 The VGR values provided an insight into the 
relationships between patient safety and warfarin-related knowledge and satisfaction. In this 
study, patients with a poor VGR had a better knowledge score compared to any other 
category. Thus suggesting that warfarin-related knowledge may not be a significant predictor 
of changes in VGR. The patients monitored at CRH and HRI clinics was not significantly 
different in terms of hospital admissions or adverse effects. Similarly, another found that 
there was no significant difference in the number of warfarin-related hospital admissions and 
the type of monitoring service offered.20 This reinforces the importance of considering 
patient-related factors when discussing hospital admissions. On the other hand, a study 
conducted by Rudd & Dier (2010), found that pharmacist-managed anticoagulant services 
significantly improved patient safety by reducing the number of anticoagulation-related 
events.21
In this study, HRI had a slightly higher overall satisfaction score. Patient satisfaction is an 
important variable when discussing warfarin treatment. It can ultimately affect the quality of 
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life of patients. Murray et al., (2005) conducted a study with 28 participants on long-term 
warfarin therapy and found that warfarin therapy reduced the quality of life of patients, with 
28% of patients reported that warfarin treatment had a negative impact on their work.22 This 
highlights the effect of poor satisfaction with warfarin treatment and the warfarin service. 
They also found that patients attending anticoagulation clinics as opposed to primary care 
surgeries felt that attending the clinics were an inconvenience due to the location. Similarly, 
appointments at CRH were less time consuming as patients were just required to undergo a 
finger-prick test. Whereas, patients at HRI had less flexibility when attending the clinic as they 
were required to attend at a specific time. Nevertheless, patients were given dose 
adjustments immediately. 
As warfarin has a narrow therapeutic index, close monitoring is essential.23 Thus, it is critical 
patients can contact the anticoagulation team with any queries. It is important to note that 
patients with poor INR control may benefit from speaking to a specialist healthcare 
professional face-to-face. However, patients from CRH do not have this opportunity; thus 
they have to rely on telephone consultations. Research shows that face-to-face contact has 
more impact on counselling as opposed to telephone consultations. For example, Hewitt et 
al., (2010) conducted a study at eight GP surgeries in Scotland and found that telephone 
consultations were shorter and included less discussion of problems as opposed to face-to-
face consultations.24 This is consistent with the present study as patients from HRI displayed 
better anticoagulant control. Moreover, the literature has suggested that patients feel more 
comfortable with face-to-face interaction in comparison to telephone consultations. Bungard 
et al., (2013) assessed the patient satisfaction amongst multidisciplinary anticoagulation 
clinics and found that patients preferred the care they received from a face-to-face 
anticoagulant clinic as opposed to visiting their GP.25
Warfarin-related knowledge is an essential indicator of the comparison between two services. 
However, in our study, only half of the participants across both sites felt that they received 
counselling on the use of warfarin. As mentioned, the advice is a necessity in all cases where 
medication is involved mainly in patients taking ‘high-risk' medicines such as warfarin.26 Thus, 
the target for all patients is to ensure that clear counselling is provided and reinforced during 
their initial therapy and throughout their warfarin journey. The NHS offers checklists for 
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hospital staff to complete when counselling patients on warfarin.27 The importance of 
counselling can be found in a study conducted by Collins in 2014 where patients warfarin-
related knowledge improved from an average of 65% to 82% after patients received verbal 
counselling.28 Another study by Lakshmi (2013) found that patients knowledge improved 
significantly upon the introduction of counselling.29 
The cost of running the warfarin monitoring service at CRH was higher in this study (£11.06 
per patient per visit) compared to £9.70 per patient, per visit at HRI. Despite HRI providing 
more clinics, fewer patients attended the clinic compared to CRH. On average, CRH monitors 
52 patients per day, whereas HRI monitors an average of 27 patients per day. The clinic 
opening times may be responsible for this. CRH clinics operate for 140 hours per month, while 
HRI operated for 78 hours per month. When discussing the number of patients per day, it is 
crucial to consider the time spent when dosing these patients. 
Furthermore, when analysing the cost data from CRH, it is vital to consider the cost of 
telephone calls and postage. A ‘post and dose' service requires the clinic to send dose 
adjustments via the post.  Thus, postage is an essential aspect of the service which can 
significantly impact the total cost of running a clinic. Finally, the cost of consumables affected 
the total cost of the services. Although the cost of consumables was identical across both 
sites, costs vary depending on the number of items and patients monitored in both clinics. 
When interpreting the data presented in this study, it is essential to consider the limitations 
associated with this study such as sample size, cross-sectional study design and non-
probability sampling. The present study aimed to estimate the costs of service delivery in two 
hospitals which consitiuted only a part of the the overall service provision. On the other hand, 
indirect costs are also a vital factor to consider. Indirect costs can significantly affect patient 
satisfaction and safety. For example, increased waiting time and longer follow-up 
consultations can reduce patient satisfaction.  Furthermore, the cost of treating adverse 
events can play a crucial role in the comparison between different service models.  
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5. Conclusion
This study has successfully highlighted the similarities and differences between a  face-to-face 
clinic and a post and dose service while assessing warfarin-related knowledge, safety 
indicators, patient satisfaction and cost of service delivery. Patients from HRI had a marginally 
higher knowledge score and satisfaction rating compared with patients from CRH. Although, 
HRI provided monitoring service at a slightly lower cost than CRH, patients monitored at CRH 
had better anticoagulation control and favourable safety indicators. A cost-effective warfarin 
monitoring service is essential to improve patient satisfaction, warfarin-related knowledge 
and patient safety. Overall, the data within this study shows the importance of incorporating 
all four characteristics to provide the best possible care for warfarin patients attending a 
warfarin monitoring service.
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Table 1: Socio-demographic data and warfarin-related factors, by CRH and HRI (n=160)
Variable Total
n (%)
CRH
n (%)
HRI
n (%)
p-value
Mean age (SD) 70.61 
(14.39)
71.69 
(14.43)
69.53 
(14.36)
0.344
Age Groups
18-63 41 (25.6) 18 (22.5) 23 (28.7)
64-74 42(26.3) 21 (26.3) 21 (26.3)
75-80 39 (24.4) 20 (25) 19 (23.8)
>80 38 (23.7) 21 (26.3) 17 (21.2)
0.788
Sex
Male 91 (56.9) 47 (58.8) 44 (55.0)
Female 69 (43.1) 33 (41.2) 36 (45.0)
0.632
Warfarin indication
AF 81 (50.6) 40 (50.0) 41 (51.2)
PE 19 (11.9) 8 (10.0) 11 (13.8)
DVT 16 (10) 8 (10.0) 8 (10.0)
Mechanical heart 
valve
26 (16.2) 15 (18.7) 11 (13.8)
Other 18 (11.2) 9 (11.2) 9 (11.2)
0.894
Duration of warfarin (months)
6-12 6 (3.8) 4 (5.0) 2 (2.5)
13-18 12 (7.5) 5 (6.2) 7(8.8)
19-24 9 (5.6) 4 (5.0) 5 (6.2)
>24 133 (83.1) 67 (83.8) 66 (82.5)
0.773
Note: p-value calculated using Chi-Square test of proportionality. SD; standard deviation, N; Number 
of participants, HRI; Huddersfield Royal Infirmary, CRH; Calderdale Royal Hospital, AF; Atrial 
Fibrillation, PE; Pulmonary Embolism, DVT; Deep Vein Thrombosis, Other; for example, cerebral 
embolism, femoral popliteal bypass surgery.
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Table 2: Summary of patients’ experience with warfarin therapy
Total
YES
HRI
YES
CRH
YES
Statement
n (%) n (%) n (%)
p-
value
Have you been admitted to hospital 
in last one year?
40 
(25.0)
21 
(26.2)
19 
(23.7)
0.715
If yes, for how long in total? mean 
(range) days
3.6
(0 – 90)
2.1
(0 – 77)
10.0
(1 – 90)
If admitted into hospital, was this 
because of warfarin?
3 
(1.9)
2 
(2.5)
1 
(1.2)
0.560
If yes, how many times? mean 
(range) times
0.04
(0 – 1)
0.02
(0 – 1)
1.0
(1 – 1)
Have you previously experienced 
any side effect (e.g. bleeding) 
because of anticoagulant (warfarin)?
21 
(13.1)
8 
(10.0)
13 
(16.2)
0.242
If yes, how many times? mean 
(range) times
0.3
(0 – 3)
0.1 
SD = 0.3
1.6
(1 – 3)
On a daily basis, do you currently 
take your medicines yourself 
without supervision (self-
administered) or support?
142 
(88.7)
69 
(86.2)
73 
(91.2)
0.349
Note: p-value calculated using Chi-Square test of proportionality. N; Number of participants, HRI; 
Huddersfield Royal Infirmary, CRH; Calderdale Royal Hospital
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Table 3: Participant’s warfarin-related knowledge, by type of service model
Total HRI CRHItem
Yes
n 
(%)
No
n 
(%)
Yes
n 
(%)
No
n 
(%)
Yes
n 
(%)
No
n 
(%)
Warfarin does affect the blood (Q1)     102 
(69.9
)
44 
(30.1
)
59 
(40.4
)
14 
(9.6)
43 
(29.4
)
30 
(20.5
)
Warfarin thins the blood (Q2)    
                 
138 
(93.9
)
9 
(6.1)
74 
(50.3
)
1 
(0.7)
64 
(43.5
)
8 
(5.4)
Warfarin thickens the blood (Q3)     
          
14 
(10.1
)
125 
(89.9
)
8 
(5.8)
63 
(45.3
)
6 
(4.3)
62 
(44.6
)
Alcohol does affect warfarin 
treatment (Q4) 
  
79 
(57.7
)
58 
(42.3
)
33 
(24.1
)
26 
(19.0
)
46 
(33.6
)
32 
(23.4
)
Do you know which drugs should be 
avoided when receiving warfarin 
treatment? (Q5)
80 
(53.7
)
69 
(46.3
)
35 
(23.5
)
41 
(27.5
)
45 
(30.2
)
28 
(18.8
)
Do you know which food items 
should be avoided when taking 
warfarin? (Q6)
109 
(74.1
)
38 
(25.9
)
54 
(36.7
)
24 
(16.3
)
55 
(37.4
)
14 
(9.5)
Will starting a new medicine, or any 
other preparation affect your 
warfarin treatment? (Q7)
109 
(83.2
)
22 
(16.8
)
52 
(39.7
)
13 
(9.9)
57 
(43.5
)
9 
(6.9)
Will changing the dose of a medicine 
you are already taking affect your 
warfarin? (Q8)
108 
(75.0
)
36 
(25.0
)
47 
(32.6
)
19 
(13.2
)
61 
(42.4
)
17 
(11.8
)
Number of correct answers, 
mean (SD)
5.02 (1.78) 5.22 (1.86) 4.83 (1.67)
Overall knowledge percentage, 
mean (SD)
62.74 (22.19) 65.22 (23.29) 60.31 (20.93)
Note: P-value calculated using Chi-Square test of proportionality. N; Number of participants, HRI; 
Huddersfield Royal Infirmary, CRH; Calderdale Royal Hospital
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Table 4: Patient satisfaction with the warfarin monitoring service at HRI and CRH
Total
n=160
HRI
n=80
CRH
n=80
Statement Response 
in 
agreeme
nt
n 
(%)
n 
(%)
n 
(%)
Have you got a yellow warfarin 
book? (4a)
Yes 136 
(85.0)
79 
(98.7)
57 
(71.2)
Is the dose of warfarin written 
clearly in the yellow book? (4b)
Yes 119 
(74.4)
77 
(96.2)
42 
(52.5)
Do you know when and where 
your next blood test is? (4c)
Yes 77 
(48.7)
77 
(96.2)
0 
(0.0)
Were you given counselling on the 
use of warfarin? (4d)
Yes, and 
clear
90 
(56.6)
50 
(62.5)
40 
(50.0)
Was the advice clear and easy to 
understand? (4e)
Yes 110 
(69.6)
52 
(65.0)
58 
(72.5)
Were you told about the 
importance of blood monitoring, 
and was this clear to you? (4f)
Yes, and 
clear
128 
(81.0)
73 
(91.2)
55 
(68.7)
Were you told of the actions to be 
taken in case of missed doses, 
and was this clear to you? (4g)
Yes, and 
clear
95 
(59.4)
57 
(71.2)
38 
(47.5)
Have you been given details of 
what to do in an emergency?  (4h)
Yes 82 
(51.6)
51 
(63.7)
31 
(38.7)
Have you needed to telephone 
the Anticoagulation helpline in the 
last year? (4i)
Yes 43 
(39.1)
21 
(26.2)
22 
(27.5)
If YES, how satisfied are you with 
our helpline service?  (4j)
Very 
satisfied or 
satisfied
100 
(62.5)
21 
(26.2)
79 
(98.7)
How do you rate the care given by 
our staff? (4k)
Excellent 
or Good
156 
(97.5)
77 
(96.2)
79 
(98.7)
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223
224
How would you rate the warfarin 
monitoring service as a whole? 
(4l)
Excellent 
or Good
158 
(98.7)
79 
(98.7)
79 
(98.7)
Overall satisfaction score, mean (SD) 
(possible range: 0 – 21)
15.32 
(3.13)
15.59 
(3.16)
15.05 
(3.10)
P-value calculated using Chi-Square test of proportionality. N; Number of participants, HRI; Huddersfield 
Royal Infirmary, CRH; Calderdale Royal Hospital
Table 5: The safety indicators, comparing the INR control of patients at HRI and CRH
Total HRI CRHItem
n=160 n=80 n=80 p-value
Mean INR 2.60 2.56 2.65 0.170
SD/ 
Range
0.38/
1.95-3.90
0.32/
1.95-3.45
0.43/
2.10-3.90
-
No of INR > 1 below Target 
(in last one year)
42 
(26.2%)
20 
(25.0%)
22 
(27.5%)
0.719
No of INR > 1 above target
(in last one year)
85 
(53.1%)
43 
(53.7%)
42 
(52.5%)
0.874
No of INR above 4
(in last one year)
52 
(32.5%)
21 
(26.2%)
31 
(38.7%)
0.091
No of INR above 5
(in last one year)
18 
(11.3%)
10 
(12.5%)
8 
(10.0%)
0.617
Mean TTR 69.15 68.70 69.63 0.756
SD/ 
Range
18.56/ 
27-100
19.43/
29-100
17.71/
27-100
-
Poor TTR (<39%) 10
(6.2%)
5
(6.2%)
5
(6.2%)
Below Average TTR (57-39%) 27 
(16.9%)
17 
(21.2%)
10 
(12.5%)
Average TTR (69-57%) 43 
(26.9%)
22 
(27.5%)
21 
(26.2%)
Good TTR (82-69%) 37 
(23.1%)
15 
(18.7%)
22 
(27.5%)
Excellent TTR (>82%) 38 
(23.7%)
21 
(26.2%)
17 
(21.2%)
0.489
Mean VGR (>24 months) 0.25 0.35 0.17 0.092
SD/ 
Range
0.43/ 
0.0-2.70
0.62/
0.0-2.70
0.17/
0.01-0.66
-
Note: P-value calculated using Chi-Squared & Independent t-test. N; Number of participants, HRI; 
Huddersfield Royal Infirmary, CRH; Calderdale Royal Hospital, SD; standard deviation
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Table 6: Estimated Costs associated with warfarin monitoring services at CRH and HRI
Item HRI CRH
Number of clinics (average)a 6/week 5/week
Number of patients (average) 27/day 52/day
Total time (avg min per patient) f 7min 12min
Number of doctors (avg. per day/clinic) NIL NIL
Number of nurses (avg. per day/clinic) 1 1
Number of pharmacists (avg. per day/clinic) 1 1
Number of phlebotomists (avg/clinic) NIL 1
Administrator (avg. per day/clinic) 1 1
Clerical assistant (avg. per day/clinic) b 1 1
Estimated 
Cost
Estimated 
Cost
Point-of-care testing* £3.74 £3.74
a) INR test strip (per test strip) £2.05 £2.05
b) Consumables (gloves, tissue, plaster, medical 
waste wastage discharge, lancing device)
£0.30 £0.30
c) Cost of POC-INR device (based on depreciation 
over five years) c
£1.39 £1.39
Quality assurance/quality control £3.13 £3.73
a) Quality control test (if any, e.g. QC? QA costs, 
Coaguchek XS control test)
£3/test £3.60/test
b) External quality assurance programme (if any, 
e.g. Royal society program) h
£0.13/test £0.13/test
Fee for service (if any) NIL NIL
Professional fees £2.19 £3.28
a) Health Professional time (per patient per visit) e 
e.g nurse
£1.03 £1.18
b) Other staff (per patient per visit), e.g. clerical 
staff
£1.16 £2.10
Miscellaneous Costs £0.64 £0.91
a) Postage from monitoring service (per patient per 
visit) g
£0.33 £0.67
b) Telephone calls (per patient per visit £0.31 £0.24
No. of telephone calls to patients (on a typical clinic 
day) at 14p/min
£1.68/day £2.24/day
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Cost (per patient per visit) * £9.70 £11.06
Cost (per patient per year) * £116.40 £132.72
Total Cost (per clinic per day) * £261.90 £575.12
Total Cost (per clinic per year) * £81,712.80 £149,531.20
*= Based on low test frequency of one test or visit/ month. HRI (12x1x27) = 324 tests per year CRH (12x1x52) = 624 tests per year.
a. CRH clinics are from 8 – 3pm Mon to Fri = 140hrs/month; HRI clinics are approx. 5 x 3.5 hours and 1 x 2 hours = 78hrs/month
b. Approx. 5 hrs/day answering the phone for changing appointments and following up missed appointments etc. – at both services
c. Cost = £3000; Salvage value = £500; Total depreciation = £2500
Monthly depreciation = (2500/5) ÷ 12 = £41.67; Daily depreciation = £1.39
d. Machines are Qc’d at HRI in batches as more machines are available hence less frequently performed. Machines have been updated at CRH, 
and the new solutions are more expensive. All machines are Qc’d before each clinic (HRI: 4 times a week; CRH: 5 times a week).
e. Estimated using national average salary for a Nurse: £25,820/365days 
f. CRH: 4min for blood test+ 1 for Apex transfer of result+ 7 min for ringing with dose change. Waiting time is not included. 
g. Approx. 50% of those attending clinic may need a phone call. Everyone with a dosage change receives a call. Estimated using First class post
h. The same frequency for both sites every two months
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